Navigation Links
Kibow Biotech, Inc. to Present at BIO 2009 International Convention: Innovations to Heal, Fuel, and Feed the World
Date:5/14/2009

NEWTOWN SQUARE, Pa., May 14 /PRNewswire/ -- The Philadelphia area-based probiotics firm Kibow Biotech will be one of only three (3) Pennsylvania companies invited to present at the BIO 2009 Company Forum, http://www.convention.bio.org, in Atlanta, GA on Tuesday, May 19. BIO is the world's largest biotechnology organization, providing advocacy, business development and communications services for more than 1,200 member companies and institutions worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies.

Dr. Natarajan Ranganathan, Interim CEO and Senior VP (R&D) of Kibow Biotech, stated, "It is indeed an honor to be selected to be part of this forward-looking group of biotech leaders. I will be presenting the technology and accomplishments of Kibow Biotech, which include the recent launch of Kibow Biotics(R), a patented and proprietary probiotic formulation in support of renal health. Our veterinary formulation, for dogs and cats with moderate to severe kidney failure, has been successfully sold on the North American market for the past three years." The veterinary product is called Azodyl(TM) and is marketed by Vetoquinol - USA, Fort Worth, Texas.

Kibow Biotics was made available in the US (http://www.kibow.com) and in Canada (http://www.gelda.com) in April 2009. The product is a dietary supplement and not a drug; it is not intended to be used as a drug or as a substitute for any drug application. The Company encourages referrals from healthcare professionals, even though Kibow Biotics i
'/>"/>

SOURCE Kibow Biotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Kibow Biotech, Inc. Launches Breakthrough Probiotic Dietary Supplement for Kidney Health in USA and Canada
2. Kibow Biotech Strongly Supports World Kidney Day for Maintenance of Healthy Kidney Function
3. ALS Therapy Development Institute, the Worlds Largest Non-Profit Biotech, Appoints Steve Perrin, Ph.D., as Chief Executive Officer
4. Crystal Research Associates, LLC Issues an Executive Informational Overview(R) (EIO(R)) on ACT Biotech, Inc.
5. Ortho Biotech, L.P. and Centocor, Inc. Alert Authorized Distributors and Prescribing Physicians About Stolen Product
6. Lilly CEO Praises Massachusetts Leadership in Biotech, Urges Policy Prescriptions to Help Ensure States Investment Generates Dividends and Jobs
7. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
8. Venture Capitalists Bullish on Greentech and Biotech, KPMG Study Says
9. China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results
10. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
11. PAREXEL Consulting Experts To Present Insights Into Achieving Regulatory Approval at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)LELYSTAD, The Netherlands, December 2 Pepscan Holding NV,the Netherlands based biotechnology company focusing on protein mimicking,technology for the generation of immune therapeutics today announced
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
(Date:12/2/2009)QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: AEZ) (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today annou
(Date:12/2/2009)HOBOKEN, N.J., Dec. 2 According to the National Institute of Health, 40 percent to 45 percent of Americans diagnosed with diabetes already have some stage of diabetic retinopathy. Diabetic retinopat
Breaking Biology Technology:Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 2Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 3Study Shows Pine Bark Improves Microcirculation, Retinal Swelling And Visual Acuity In Early Diabetic Retinopathy 4
...barely cover a human thumbnail, but they can hold ...cause this emerging technology offers a view of so...ct for studying relationships among the 30,000 gen... next major mysteries. , ,Biochips, essentially sl...m, give scientists a chance to look at bits of DNA...
... Computer Systems unit of Milwaukee-based Fiserv ...offer a product that verifies customers, identitie...nsightID provides access to billions of public rec...der of banking technology, and InsightAmerica, a s...nce to help prevent fraud losses from identity the...
...Sensient Technologies Corp. (NYSE:SXT) reported $...ues for its first quarter ended March 31. Diluted ...obal manufacturer and marketer of colors, flavors ...ce the same quarter last year. Total debt was $596... for the first quarter include a one-time expense ...
Other Biology Technology:Madison biochip research offers geneticists a big view through a small window 2Madison biochip research offers geneticists a big view through a small window 3
(Date:12/2/2009)...acculturated Latino men have a more difficult time...ated to U.S. culture, but acculturation has no aff...f these findings are published in Cancer Epidemio...merican Association for Cancer Research. The Decem...lturation affects smoking cessation differently fo...
(Date:12/2/2009)...e who smoke their first cigarette within minutes a..., a by-product of nicotine when processed by the b...he number of cigarettes smoked. , "Since cotin...er, our results suggest that smokers who smoke imm...r lung cancer," said researcher Joshua E. Muscat, ...
(Date:12/2/2009)...nce of a cancer-free status did not prompt people ...hy (CT) lung-cancer screening program to pick up t...y published in Cancer Epidemiology, Biomarkers & ... for Cancer Research. The December issue contains ...ld negate widespread concern in the lung screening...
Breaking Biology News(10 mins):Acculturation affects smoking cessation success among Latinos 2Increased nicotine levels detected in those who light-up earlier 2Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2Advanced Heart Procedure Treats Growing Problem 51120 1Advanced Heart Procedure Treats Growing Problem 51120 2Advanced Heart Procedure Treats Growing Problem 51120 3Screen All Newborns for Hip Dysplasia Study Urges 51115 1Screen All Newborns for Hip Dysplasia Study Urges 51115 2B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 1B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 2B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 3B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 4B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 5B Line Medical 28R 29 and Surgical Science Sign Data Integration Agreement for LapSim 28R 29 Simulator 51109 6
...rding to scientific gospel, social behavior is dic...as food, territory and reproduction. , That may we...breaking study researchers from the University of ...interactions among young mice result from basic mo... researchers say, the extent of a young mouse,s gr...
... fruit fly is able to locate and blissfully drown ...ially since its flight path seems to be so erratic...dy Reynolds at Rothamsted Research in the United K...Fruit flies explore their environment using a seri...° body-saccades. Some of these manoeuvres avoid ob...
...ts to developing new antibiotics, and a technique ...locking those secrets. , That,s the view of Unive...y, who will discuss his group,s progress toward th...ysical Society in Baltimore, Md. , Ramamoorthy,...re the germ-killing properties of natural antibiot...
Other Biology News:In young mice, gregariousness seems to reside in the genes 2In young mice, gregariousness seems to reside in the genes 3Flies don't buzz about aimlessly! 2Natural antibiotics yield secrets to atom-level imaging technique 2Natural antibiotics yield secrets to atom-level imaging technique 3
IMAGEQUANT 400 WKSTN from GE Healthcare, formerly Amersham Biosciences
Rabbit Anti-Human IFN-Alpha / Beta R2 (IFNAR2) (CD118) Neutralizing Polyclonal Antibody, Unconjugated from PBL InterferonSource
Rabbit Anti-MYCOBACTERIUM TUBERCULOSIS Polyclonal Antibody, Unconjugated from AbD Serotec
ImageQuant 400 from GE Healthcare, formerly Amersham Biosciences
Biology Products: